Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS

Deborah N Schoonhoven; Matteo Fraschini; Prejaas Tewarie; Bernard Mj Uitdehaag; Anand Jc Eijlers; Jeroen Jg Geurts; Arjan Hillebrand; Menno M Schoonheim; Cornelis J Stam; Eva Mm Strijbis

doi:https://doi.org/10.1177/1352458518810260

Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS

Deborah N Schoonhoven, Matteo Fraschini, Prejaas Tewarie, Bernard Mj Uitdehaag, Anand Jc Eijlers, Jeroen Jg Geurts, Arjan Hillebrand, Menno M Schoonheim, Cornelis J Stam, Eva Mm Strijbis

Research output: Contribution to journal › Article › Academic › peer-review

18 Citations (Scopus)

Abstract

BACKGROUND:: Neurophysiological measures of brain function, such as magnetoencephalography (MEG), are widely used in clinical neurology and have strong relations with cognitive impairment and dementia but are still underdeveloped in multiple sclerosis (MS).

OBJECTIVES:: To demonstrate the value of clinically applicable MEG-measures in evaluating cognitive impairment in MS.

METHODS:: In eyes-closed resting-state, MEG data of 83 MS patients and 34 healthy controls (HCs) peak frequencies and relative power of six canonical frequency bands for 78 cortical and 10 deep gray matter (DGM) areas were calculated. Linear regression models, correcting for age, gender, and education, assessed the relation between cognitive performance and MEG biomarkers.

RESULTS:: Increased alpha1 and theta power was strongly associated with impaired cognition in patients, which differed between cognitively impaired (CI) patients and HCs in bilateral parietotemporal cortices. CI patients had a lower peak frequency than HCs. Oscillatory slowing was also widespread in the DGM, most pronounced in the thalamus.

CONCLUSION:: There is a clinically relevant slowing of neuronal activity in MS patients in parietotemporal cortical areas and the thalamus, strongly related to cognitive impairment. These measures hold promise for the application of resting-state MEG as a biomarker for cognitive disturbances in MS in a clinical setting.

Original language	English
Pages (from-to)	1896-1906
Journal	MULTIPLE SCLEROSIS JOURNAL
Volume	25
Issue number	14
Early online date	22 Nov 2018
DOIs	https://doi.org/10.1177/1352458518810260
Publication status	Published - 1 Dec 2019

Access to Document

https://doi.org/10.1177/1352458518810260

Cite this

@article{069c9ddd75de4ea7ae42e2ab2e846be2,

title = "Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS",

abstract = "BACKGROUND:: Neurophysiological measures of brain function, such as magnetoencephalography (MEG), are widely used in clinical neurology and have strong relations with cognitive impairment and dementia but are still underdeveloped in multiple sclerosis (MS).OBJECTIVES:: To demonstrate the value of clinically applicable MEG-measures in evaluating cognitive impairment in MS.METHODS:: In eyes-closed resting-state, MEG data of 83 MS patients and 34 healthy controls (HCs) peak frequencies and relative power of six canonical frequency bands for 78 cortical and 10 deep gray matter (DGM) areas were calculated. Linear regression models, correcting for age, gender, and education, assessed the relation between cognitive performance and MEG biomarkers.RESULTS:: Increased alpha1 and theta power was strongly associated with impaired cognition in patients, which differed between cognitively impaired (CI) patients and HCs in bilateral parietotemporal cortices. CI patients had a lower peak frequency than HCs. Oscillatory slowing was also widespread in the DGM, most pronounced in the thalamus.CONCLUSION:: There is a clinically relevant slowing of neuronal activity in MS patients in parietotemporal cortical areas and the thalamus, strongly related to cognitive impairment. These measures hold promise for the application of resting-state MEG as a biomarker for cognitive disturbances in MS in a clinical setting.",

author = "Schoonhoven, {Deborah N} and Matteo Fraschini and Prejaas Tewarie and Uitdehaag, {Bernard Mj} and Eijlers, {Anand Jc} and Geurts, {Jeroen Jg} and Arjan Hillebrand and Schoonheim, {Menno M} and Stam, {Cornelis J} and Strijbis, {Eva Mm}",

year = "2019",

month = dec,

day = "1",

doi = "https://doi.org/10.1177/1352458518810260",

language = "English",

volume = "25",

pages = "1896--1906",

journal = "MULTIPLE SCLEROSIS JOURNAL",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "14",

}

TY - JOUR

T1 - Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS

AU - Schoonhoven, Deborah N

AU - Fraschini, Matteo

AU - Tewarie, Prejaas

AU - Uitdehaag, Bernard Mj

AU - Eijlers, Anand Jc

AU - Geurts, Jeroen Jg

AU - Hillebrand, Arjan

AU - Schoonheim, Menno M

AU - Stam, Cornelis J

AU - Strijbis, Eva Mm

PY - 2019/12/1

Y1 - 2019/12/1

N2 - BACKGROUND:: Neurophysiological measures of brain function, such as magnetoencephalography (MEG), are widely used in clinical neurology and have strong relations with cognitive impairment and dementia but are still underdeveloped in multiple sclerosis (MS).OBJECTIVES:: To demonstrate the value of clinically applicable MEG-measures in evaluating cognitive impairment in MS.METHODS:: In eyes-closed resting-state, MEG data of 83 MS patients and 34 healthy controls (HCs) peak frequencies and relative power of six canonical frequency bands for 78 cortical and 10 deep gray matter (DGM) areas were calculated. Linear regression models, correcting for age, gender, and education, assessed the relation between cognitive performance and MEG biomarkers.RESULTS:: Increased alpha1 and theta power was strongly associated with impaired cognition in patients, which differed between cognitively impaired (CI) patients and HCs in bilateral parietotemporal cortices. CI patients had a lower peak frequency than HCs. Oscillatory slowing was also widespread in the DGM, most pronounced in the thalamus.CONCLUSION:: There is a clinically relevant slowing of neuronal activity in MS patients in parietotemporal cortical areas and the thalamus, strongly related to cognitive impairment. These measures hold promise for the application of resting-state MEG as a biomarker for cognitive disturbances in MS in a clinical setting.

AB - BACKGROUND:: Neurophysiological measures of brain function, such as magnetoencephalography (MEG), are widely used in clinical neurology and have strong relations with cognitive impairment and dementia but are still underdeveloped in multiple sclerosis (MS).OBJECTIVES:: To demonstrate the value of clinically applicable MEG-measures in evaluating cognitive impairment in MS.METHODS:: In eyes-closed resting-state, MEG data of 83 MS patients and 34 healthy controls (HCs) peak frequencies and relative power of six canonical frequency bands for 78 cortical and 10 deep gray matter (DGM) areas were calculated. Linear regression models, correcting for age, gender, and education, assessed the relation between cognitive performance and MEG biomarkers.RESULTS:: Increased alpha1 and theta power was strongly associated with impaired cognition in patients, which differed between cognitively impaired (CI) patients and HCs in bilateral parietotemporal cortices. CI patients had a lower peak frequency than HCs. Oscillatory slowing was also widespread in the DGM, most pronounced in the thalamus.CONCLUSION:: There is a clinically relevant slowing of neuronal activity in MS patients in parietotemporal cortical areas and the thalamus, strongly related to cognitive impairment. These measures hold promise for the application of resting-state MEG as a biomarker for cognitive disturbances in MS in a clinical setting.

U2 - https://doi.org/10.1177/1352458518810260

DO - https://doi.org/10.1177/1352458518810260

M3 - Article

C2 - 30465461

SN - 1352-4585

VL - 25

SP - 1896

EP - 1906

JO - MULTIPLE SCLEROSIS JOURNAL

JF - MULTIPLE SCLEROSIS JOURNAL

IS - 14

ER -